FNA: Paragon 28 Inc. Price to Sales

Symbol and logo of brand Paragon 28 Corp (FNA)

Paragon 28, Inc. (FNA) is expanding through new surgical solutions and the shift of procedures to the outpatient sector. The current price-to-sales ratio reflects the market valuation of the business, where 4.30 is the current value of the metric. The company's economics rely on the mass production of high-margin titanium products, while the intensive development of robotic systems and orthopedic fixators ensures a technological breakthrough.

FNA (Paragon 28 Corp) P/S Multiple history from 07/04/2022 to 04/26/2025

Analytical breakdowns for Paragon 28, Inc. (FNA)

- market price and analyst price targets:
Stock Quotes paragon28.com|FNA - Analyst Consensus Forecast
- market capitalization information:
Market Value Paragon 28 Corp|FNA - Enterprise Value
- shareholders' equity book value data:
Equity per Share Paragon 28|FNA - Book Capitalization|Market Capitalization to Book Value paragon28.com|FNA - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Paragon 28, Inc.|FNA - Long-Term Debt to Capital|Short-Term Debt to Capital paragon28.com|FNA - Company Debts|Debt to Book Capitalization Ratio Paragon 28 Corp|FNA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Paragon 28|Immediate Liquidity paragon28.com
- net income and valuation multiples indicators:
FNA - Company Net Income|Projected Net Profit Paragon 28, Inc.|FNA - Price to Earnings Ratio|Forward P/E Multiple paragon28.com|FNA - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Paragon 28 Corp|FNA - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Paragon 28|FNA - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months paragon28.com|FNA - Earnings growth in current year|Expected net earnings per share growth next year Paragon 28, Inc.
- issuer revenue and sales details:
FNA - Company Revenue|Company Revenue Forecast paragon28.com|FNA - Market Cap to Revenue|Price to Expected Revenue Ratio Paragon 28 Corp
Fundamental company analysis:Paragon 28 Inc. FNA
Original product of Paragon 28, Inc.

The multiplier assesses the market value of the business relative to its annual revenue, allowing the investor to identify asset undervaluation through an analysis of the price-to-sales ratio. This coefficient is calculated by dividing the market capitalization of Paragon 28, Inc. (FNA) by its sales volume, reflecting the monetization efficiency of innovative orthopedic solutions and the effectiveness of the sales staff incentive system.

Who Paragon 28, Inc. competes with

Market Cap to Revenue bostonscientific.com BSX|P/S Multiple EW (Edwards Lifesciences Corporation)|ResMed Inc (RMD) - Price to Sales|OmniPod - P/S Multiple|ZBH (Zimmer Biomet Holdings) - Market Cap to Revenue Ratio|COO: P/S Multiple|ALGN - Price-to-Revenue Coefficient|GMED (Globus Medical) - P/S Multiple|Market Cap to Revenue TransMedics Group Inc (TMDX)|P/S Multiple ATEC|P/S Multiple Artivion Corp (AORT)|Price-to-Revenue Ratio Enovis Corporation ENOV|integralife.com - Price-to-Revenue Ratio|ESTA: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio BBNX (Beta Bionics, Inc.)|IRMD: P/S Multiple|Price to Sales Embecta Health (EMBC)|Price-to-Revenue Ratio Tandem Diabetes Care|AXGN - Price-to-Revenue Multiple|Market Cap to Revenue SIBN (SI-BONE)|P/S Multiple Orthofix Medical (OFIX)|P/S Multiple BVS (Bioventus Corp)|Price-to-Revenue Coefficient OrthoPediatrics Corp (KIDS)|TMCI - Price-to-Revenue Ratio|Price-to-Sales Ratio SRTA|Carlsmed (CARL) - Price-to-Revenue Ratio|Market Cap to Revenue RxSight Inc|CLPT (ClearPoint Neuro Inc.) - P/S Multiple|Price to Sales Stereotaxis Corporation STXS|Price-to-Revenue Ratio Neuronetics, Inc. (STIM)|sightsciences.com - Market Cap to Revenue Ratio|Orchestra BioMed, Inc. - Market Cap to Revenue|Market Cap to Sales Volume ANIK (Anika Therapeutics Inc.)|NSPR - Price-to-Revenue Ratio|Price-to-Sales Ratio ZJYL|VANI: P/S Multiple|Xtant Medical (XTNT) - P/S Multiple|Price-to-Revenue Ratio NeuroOne Medical Technologies Corporation|MODD: Market Capitalization-to-Revenue Ratio|P/S Multiple MYO|P/S Multiple Envoy Medical Inc (COCH)|P/S Multiple VVOS (Vivos Therapeutics)|Price-to-Revenue Multiple envveno.com|SINT - Price-to-Revenue Ratio|Price to Sales Tenon Medical Inc.|ReWalk Robotics Ltd (LFWD) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio AMIX|Market Cap to Revenue IVF|BBLG: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Axonics (AXNX)|BIOL (BIOLASE Inc.) - Market Capitalization-to-Revenue Ratio|Dynatronics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio INVO